EcoDrugPlus

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSVVUG00000006057
Gene Symbol: CCR9
1 Cross references
262 Possible Orthologues:

C-X-C Chemokine Receptor Type 2-Like

Ensembl ID : ENSVVUG00000007390
Gene Symbol: LOC112922479
3 Cross references
234 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSVVUG00000014755
Gene Symbol: CXCL8
3 Cross references
181 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSVVUG00000007094
Gene Symbol: CXCR4
3 Cross references
283 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSVVUG00000001638
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSVVUG00000028391
Gene Symbol: DNMT1
3 Cross references
206 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSVVUG00000029193
Gene Symbol: TOP1
3 Cross references
270 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSVVUG00000000844
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSVVUG00000028178
Gene Symbol: TOP2B
3 Cross references
208 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSVVUG00000020706
Gene Symbol: EML4
3 Cross references
209 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSVVUG00000028960
Gene Symbol: EPHA2
3 Cross references
124 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSVVUG00000021494
Gene Symbol: EPHA3
3 Cross references
215 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).